10
Nov

Two years after Michael Yeadon and a close-knit group of Pfizer investigators managed to grab some of the pharma giant’s anti-inflammatory assets on the way out the door at Sandwich, they’ve drummed up a $33 million B round for their biotech from some U.S. and European investors. And now they’re set to launch a midstage clinical program to help determine the value of what they took with them when launching Ziarco.

…read more

Source: Fledgling Ziarco grabs a $33M transatlantic round for PhII atopic dermatitis drug

    

0 No comments